X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


Latest Post

July 10, 2019

Intended Use and Packaging Risks for Compounding Pharmacies (503Bs)

In 2015, the FDA shed light on a problematic practice within the healthcare industry involving improper, off-label use of syringes as closed container storage systems for compounded or repackaged drugs. The incidents cited revealed that interaction with rubber plungers in syringes that were not cleared for the purpose of closed container storage resulted in the loss of potency of several drugs when administration was delayed.<sup>1</sup>
Amy Kim

Amy Kim

Sr. Specialist, Scientific Communications, SA & TS

Categories

Search the Blog

Archive

{1}

{2}
{3}

{4}

  • Previous Posts
    Regulatory Check List

    July 01, 2019

    European Medicines Agency's (EMA) Strategy on Engaging with Regulatory Science

    Bettine Boltres

    Bettine Boltres, Ph.D.

    Principal, Scientific Affairs, Packaging & Delivery Systems

    SmartDose Platform

    June 27, 2019

    Industry Trends in Biologic Formulations

    Victoria Morgan

    Victoria Morgan

    Director, Segment Marketing, Global Biologics

    Load more